Wellington Management Group LLP Sells 58,646 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Wellington Management Group LLP lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 35.3% during the first quarter, Holdings Channel reports. The institutional investor owned 107,313 shares of the biopharmaceutical company’s stock after selling 58,646 shares during the period. Wellington Management Group LLP’s holdings in Vanda Pharmaceuticals were worth $1,502,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Virginia Retirement Systems ET AL purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $193,000. Capital Fund Management S.A. purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $195,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at about $196,000. AQR Capital Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at about $223,000. Finally, Algert Global LLC raised its stake in shares of Vanda Pharmaceuticals by 11.8% in the first quarter. Algert Global LLC now owns 18,223 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 1,927 shares in the last quarter. Institutional investors and hedge funds own 92.51% of the company’s stock.
Vanda Pharmaceuticals Inc. (VNDA) opened at 16.35 on Wednesday. The firm’s market capitalization is $728.43 million. Vanda Pharmaceuticals Inc. has a one year low of $10.81 and a one year high of $18.00. The stock has a 50 day moving average price of $15.25 and a 200 day moving average price of $14.52.
Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. The firm had revenue of $37.42 million for the quarter, compared to analyst estimates of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. On average, equities analysts predict that Vanda Pharmaceuticals Inc. will post ($0.70) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Wellington Management Group LLP Sells 58,646 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/07/19/wellington-management-group-llp-sells-58646-shares-of-vanda-pharmaceuticals-inc-nasdaqvnda.html.
VNDA has been the topic of several recent research reports. Jefferies Group LLC restated a “buy” rating and set a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th. Oppenheimer Holdings, Inc. began coverage on Vanda Pharmaceuticals in a research note on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 price objective on the stock. TheStreet upgraded Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th. Zacks Investment Research lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, June 7th. Finally, CIBC reiterated an “outperform” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, April 12th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $21.22.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.